Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced the publication of the full results of the AVERROES study of apixaban in The New England Journal of Medicine.

Elan plc (NYSE: ELN) and Boehringer Ingelheim have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.

In the fourth quarter of 2010, sanofi-aventis generated net sales of €7,395 million, up 0.5% on a reported basis. Exchange rate movements had a favorable effect of 6.4 percentage points, mainly due to the weaker euro versus the U.S. dollar, Japanese Yen, Brazilian Real, and Australian dollar.

The New England Journal of Medicine (NEJM) published a study that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1].

Bayer HealthCare announced that its investigational anti-cancer compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA).

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

GlaxoSmithKline (GSK) announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia®, Avandamet® and Avandaryl®) to include additional safety information and restrictions on the use of these medicines.